KBC Group NV grew its stake in Sotera Health (NASDAQ:SHC – Free Report) by 4,094.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 186,365 shares of the company’s stock after purchasing an additional 181,922 shares during the quarter. KBC Group NV owned about 0.07% of Sotera Health worth $2,549,000 at the end of the most recent quarter.
Several other institutional investors have also added to or reduced their stakes in SHC. Marshall Wace LLP raised its holdings in Sotera Health by 32.2% in the 2nd quarter. Marshall Wace LLP now owns 32,696 shares of the company’s stock worth $388,000 after purchasing an additional 7,955 shares in the last quarter. AQR Capital Management LLC increased its stake in shares of Sotera Health by 3,198.2% in the 2nd quarter. AQR Capital Management LLC now owns 511,580 shares of the company’s stock worth $6,072,000 after acquiring an additional 496,069 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of Sotera Health by 4.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 115,065 shares of the company’s stock worth $1,366,000 after acquiring an additional 4,774 shares in the last quarter. Algert Global LLC bought a new position in shares of Sotera Health in the 2nd quarter worth about $169,000. Finally, Sanctuary Advisors LLC bought a new position in shares of Sotera Health in the 2nd quarter worth about $130,000. 91.03% of the stock is currently owned by institutional investors.
Sotera Health Stock Performance
Shares of SHC stock opened at $13.71 on Friday. Sotera Health has a one year low of $10.71 and a one year high of $17.44. The company’s 50-day moving average is $13.31 and its 200 day moving average is $14.54. The company has a market capitalization of $3.88 billion, a price-to-earnings ratio of 54.84 and a beta of 1.92. The company has a debt-to-equity ratio of 4.91, a quick ratio of 2.61 and a current ratio of 2.88.
Analyst Ratings Changes
Several research analysts recently issued reports on SHC shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $17.00 price target on shares of Sotera Health in a research note on Thursday, November 21st. The Goldman Sachs Group started coverage on shares of Sotera Health in a research note on Friday, December 6th. They issued a “neutral” rating and a $14.00 price target for the company. Finally, Citigroup increased their price target on shares of Sotera Health from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Sotera Health currently has a consensus rating of “Moderate Buy” and an average price target of $16.08.
Read Our Latest Stock Report on Sotera Health
Sotera Health Company Profile
Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.
Featured Stories
- Five stocks we like better than Sotera Health
- What is the Euro STOXX 50 Index?
- ServiceNow Stock Slips, But AI Expansion Signals Long-Term Gains
- What is a Bond Market Holiday? How to Invest and Trade
- Microsoft and Meta’s AI Investment Plans Are Full Steam Ahead
- How to Use the MarketBeat Dividend Calculator
- Beyond Self-Driving Cars: Factory Automation Takes Center Stage
Receive News & Ratings for Sotera Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sotera Health and related companies with MarketBeat.com's FREE daily email newsletter.